Discover what cash wages are, how they're reported, and examples of their use in compensation, offering clarity on taxable ...

“6 in ’26” expected proof-of-concept (POC) readouts across SKYLINE and SKYWAY trials SKYLINE platform trial in ulcerative colitis (UC) recruiting faster than expected with SPY001 enrollment complete ...

Two NDA submissions expected by mid-February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough Therapy Designation from the FDA Multiple ...

An announcement from Dynamic Metals Limited ( (AU:DYM)) is now available. Dynamic Metals Limited has strengthened its balance sheet after directors and management exercised a total of 4 million ...

IonQ’s robust third-quarter performance highlights the company’s accelerating commercial adoption. It has achieved multiple technical milestones, further strengthening its position in low-error, ...

CytomX has confirmed a Q1'26 readout for additional data from its trial of CX-2051 in colorectal cancer. CTMX also now notes it plans to start combination work with CX-2051 and bevacizumab in Q1'26.

IonQ has demonstrated exceptional topline performance in the recent quarter. The company is also making rapid progress towards creating a fault-tolerant quantum system, a crucial milestone for ...

Editas Medicine (NASDAQ:EDIT) is one of the best gene-editing stocks to buy according to hedge funds. On November 10, 2025, Clear Street raised its price target on Editas Medicine (NASDAQ:EDIT) to ...

Strategic transaction supports the advancement of Decoy’s rapid computational design and manufacturing of innovative peptide conjugate therapeutics through its IMP 3 ACT™ platform Combined company has ...